Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 8/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764392 | 0.86 | CSNK1D (0.52) | CSNK1DCSNK1G2CCR5NR1H2NR1H3 | |
| SCHEMBL4071190 | 0.79 | NAMPT (0.48) | CSNK1DCSNK1G2CCR5 | |
| SCHEMBL4882005 | 0.76 | CSNK1D (0.62) | CSNK1DCSNK1G2OPRM1 | |
| SCHEMBL14208796 | 0.71 | CSNK1D (0.55) | CSNK1DCSNK1G2OPRM1KCNH2 | |
| SCHEMBL4073323 | 0.71 | CSNK1D (0.39) | CSNK1DCSNK1G2CCR5OPRM1NR1H2 | |
| SCHEMBL4256933 | 0.70 | ALDH1A1 (0.54) | ALDH1A1POLBSLC18A3 | |
| SCHEMBL4773396 | 0.69 | SCD5 (0.46) | ALDH1A1POLBKCNH2HRH3 | |
| SCHEMBL27764390 | 0.68 | MEN1 (0.44) | OPRM1ALDH1A1POLBHSD11B1SLC18A3 | |
| SCHEMBL29338182 | 0.68 | OPRM1 (0.52) | OPRM1ALDH1A1HSD11B1KCNH2ADAMTS5 | |
| SCHEMBL15200613 | 0.68 | HSD11B1 (0.49) | HSD11B1KCNH2HRH3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CSNK1D 1339/4885CSNK1G2 1657/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.